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Abstract 
Background; COPD is an inflammatory airway disease characterised by progressive airflow limitation and air 
trapping, leading to lung hyperinflation and exercise limitation.  Acute worsening of symptoms, including 
dyspnea, cough and sputum production, occurs during exacerbations which are associated with 
significantly reduced health related quality of life, and increased morbidity and mortality.  Chronic 
bronchial mucus production and productive cough are risk factors for exacerbations.  Medicines targeting 
bronchoconstriction and airway inflammation are the current mainstays of COPD therapy. However, there 
is growing concern with an increased risk of pneumonia in patients with COPD receiving regular inhaled 
corticosteroids and there is therefore a need to find safer alternative treatments. 
Previous studies have indicated that inhalation of unfractionated heparin (UFH) treats local inflammation, 
mucus hypersecretion and lung injury, without systemic anticoagulation, and is safe.  Therefore, our 
primary objective was to demonstrate that inhaled UFH significantly improves lung function (FEV1) over 21 
days of treatment in patients with COPD receiving pulmonary rehabilitation and that UFH provides a novel, 
safe and effective way of treating this complex disease.   
Methods; Forty patients with moderate to very severe COPD admitted to the IRCCS San Raffaele Pisana 
Hospital for 21 days pulmonary rehabilitation were randomised to receive nebulised inhaled UFH (75,000 
or 150,000 IU BID) or placebo for 21 days.  All patients also received nebulised salbutamol (1 mg) and 
beclomethasone dipropionate (400 µg) BID over the same period.   
Lung function was measured at day 0, 7, 14 and 21 of treatment and at a follow-up visit 7 days post-
treatment.  Exercise capacity (6MWT) and dyspnoea (Borg score) were measured before and after 
treatment.   
In pre-clinical studies, the ability of basic proteins found in COPD sputum to neutralise the anticoagulant 
activity of heparin was determined using the AMAX heparin assay kit. 
Main Results; At both doses, UFH significantly increased FVC following 7 days of treatment and 150,000 IU 
BID significantly increased FEV1 (+249±69 ml compared with placebo) at this time, an effect maintained to 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
the 28 day follow-up. Clinically significant improvement in exercise capacity and dyspnoea were seen after 
21 days of treatment with both doses of UFH. There were no serious adverse events or effects on systemic 
coagulation. Pre-clinical studies demonstrated that the basic proteins lactoferrin, platelet factor-4 (PF-4), IL-
8 and polyarginine, as a model of the eosinophil cationic protein (ECP), found in COPD sputum neutralise 
the anticoagulant activity of heparin.  
Conclusion; Inhaled nebulised UFH is safe and provides additional clinical benefit for patients with 
moderate to very severe COPD through effects that are independent of its anticoagulant activity. 
 
Key words; COPD, clinical trial, inhaled, unfractionated heparin, lung function, anticoagulant activity. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a rising major global healthcare problem associated with 
significant morbidity and mortality [1]. Current treatment options are limited [2] and none conclusively 
modify the long-term decline in lung function [3].  Currently available drugs for COPD are mostly 
bronchodilators [4,5] that provide symptomatic treatment through relief of reversible airflow obstruction, 
an important, though not universal, feature of COPD [3].  Improvement in airflow obstruction can also 
result from reduction in airway inflammation or improved clearance of mucus.  Current recommendations 
advocate the use of inhaled long-acting bronchodilators combined with inhaled corticosteroids (ICS) for 
maintenance treatment of moderate-to-severe COPD [3]. However, patients with COPD are often poorly 
responsive to corticosteroids and there may be an increased risk of pneumonia in patients taking this class 
of anti-inflammatory drugs [6].  Recently the orally active PDE4 inhibitor roflumilast has been introduced as 
an anti-inflammatory drug for the treatment of COPD, but this has been restricted to use on top of existing 
therapies in severe patients, and is dose-limited by adverse effects, particularly in the gastrointestinal 
system [7].  There is therefore a need to find new therapeutic approaches for the treatment of COPD and a 
number of novel bronchodilators [8], anti-inflammatory drugs [9] and bifunctional agents [10] are under 
development for the treatment of this disease. 
 
Studies with older mucolytic/anti-oxidant drugs such as N-acetylcysteine [11], carbocysteine [12] and more 
recently erdosteine [13] have provided evidence that targeting these components of the disease has clinical 
benefit in reducing exacerbations in patients with COPD. We have therefore investigated the effect of 
inhaled nebulised unfractionated heparin (UFH) as this drug exhibits many pharmacological properties 
including mucolytic, anti-inflammatory, anti-oxidant and wound healing properties relevant to the 
treatment of COPD [14,15].  
 
Heparin belongs to the family of polyanionic glycosaminoglycans (GAGs), polysaccharides composed of 
hexuronic acid and D-glucosamine residues joined by glycosidic linkages [16]. We previously showed that 
when subcutaneous low molecular weight heparin (enoxaparin), 20 mg daily, was added to inhaled 
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salmeterol/fluticasone propionate in patients with stable moderate COPD, FEV1 was significantly increased 
after 4 weeks of additional enoxaparin therapy, compared to a significant improvement after 12 weeks of 
standard therapy [17]. However, long-term parenteral administration of an anticoagulant is undesirable 
and many of the beneficial effects of heparin in COPD are likely to be via its non-anticoagulant actions [14].   
Inhaled nebulised UFH has previously shown to be safe and without side effects in healthy volunteers 
[18,19] and in patients with asthma, cystic fibrosis, acute lung injury or idiopathic pulmonary fibrosis, at 
doses up to 400,000 units [19-23].  The inhaled route for administration of systemic heparin, 20,000 units, 
was previously investigated in patients with COPD [24], and all of these early trials found minimal 
absorption of heparin from the respiratory tract and no adverse effects.   
 
Previous studies have indicated that inhalation of UFH treats local inflammation, mucus hypersecretion and 
lung injury without systemic anticoagulation or any incidence of pulmonary haemorrhage (20 studies, 536 
patients) [25], and was safe and effective in patients with smoke inhalation injury, acute lung injury, asthma 
and allergy, and cystic fibrosis  [26].  Heparin has multiple protein binding partners [14, 16], including the 
basic chemokine platelet factor-4 (PF-4) which is known to neutralise the anticoagulant activity of heparin 
[27].   We therefore tested the ability of PF-4 and a number of basic proteins, lactoferrin, IL-8 and 
polyarginine as a model of the eosinophil cationic protein (ECP), found in the normal and inflamed COPD 
airways, to inhibit the anticoagulant activity of heparin. 
 
Furthermore, in a pilot, randomised, double blind, placebo-controlled clinical study, we have investigated 
the effect of nebulised UFH on a range of clinically relevant endpoints in patients with moderate to very 
severe COPD undergoing pulmonary rehabilitation. 
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Methods 
Preclinical studies 
The anticoagulant activity of heparin was measured in the presence of excess Factor Xa and anti-thrombin 
III using the AMAX heparin assay kit (Trinity Biotech, Bray, Ireland).  In this assay, the residual Factor Xa is 
inversely proportional to the heparin concentration. Using this assay in the microtitre plate format, UFH 
(pig intestinal mucosa, Calbiochem) at 0.5 μg/ml gave nearly complete inhibition of Factor Xa activity 
(Figure 1). Basic proteins were added to the incubations in the concentration ranges shown to achieve 
complete neutralisation of the anti-factor Xa activity of UFH. Data was analysed by one-way ANOVA and 
Dunnetts multiple comparisons test using Graph Pad Prism (version 5) software. 
 
Clinical study design 
This study was designed as a 3 week, single-centre, randomised, double-blind, parallel-group, placebo-
controlled, clinical trial of nebulised UFH at two doses.  The study (EudraCT Number 2010-024168-16) was 
approved by the local Ethics Committee Board (Registro Pareri E/33/14), and carried out in accordance with 
the Declaration of Helsinki and Good Clinical Practice guidelines.  Written informed consent was obtained 
from all patients who participated in the trial. 
 
Patients 
Patients were recruited from the Pulmonary Rehabilitation ward of the IRCCS San Raffaele Pisana Hospital 
(Rome, Italy) following admission for treatment, usually within 7 days post-exacerbation. This study 
enrolled COPD patients (men and women, aged 50 – 85 years) with moderate to very severe airflow 
limitation (stage II to IV according to Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2014 
spirometric classification [3], forced expiratory volume in 1 second [FEV1] 20 - 70% of normal predicted and 
FEV1 / forced vital capacity [FVC]<0.7). Patients had to be current or ex-smokers with a smoking history of 
at least 20 pack years, (see Table 1).  
Exclusion criteria including hemoptysis, bleeding and pre-existing presence of heparin induced antibodies 
are described in the on-line data supplement.  
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Randomisation and masking 
Forty COPD patients were randomly assigned in a 1:1:1 ratio to receive inhaled nebulized UFH (75,000 IU or 
150,000 IU) or placebo using a computer generated permutation, with a block of three subjects.   
 
Treatments 
Patients received twice daily treatment with inhaled UFH (75,000 IU or 150,000 IU, molecular weight 
13,000, Teofarma, Italy) or placebo (distilled water) for 21 days, nebulised from a jet nebuliser 
(compressor: SpeedyMed, Italy; nebulizer: Ampolla Poly, Italy), the particles having a mass median 
aerodynamic diameter (MMAD) of 3.25 µm, and a fill volume of 7 ml.   
 
Dosing was based on our previous unpublished study of inhaled UFH in COPD (n=8, FEV1%; 52.6 (SD 30.9), 
in which we found 50,000 IU BID for 14 days was safe, but without effect on FEV1
 
and the observation that 
in healthy subjects 150,000 IU may be the top nebuliser fill before systemic effects are detected [19]. 
 
All patients received concomitant medication with salbutamol (1 mg twice daily via nebulisation) and 
beclomethasone dipropionate (400 µg twice daily via nebulisation), as well as pulmonary rehabilitation. 
However, in view of the potentially dehydrating effect of anti-cholinergics on airway secretions making 
mucus more difficult to expectorate [28], long-acting muscarinic receptor antagonists were discontinued 
with a washout of 7 days before randomization. 
 
The pulmonary rehabilitation programme was as we previously described [29], carried out over a total of 3 
weeks. 
 
Objectives, assessments, and outcome measures 
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The primary objective was to demonstrate a relatively small, but clinically significant, improvement in 
trough FEV1 of 140 ml, according to the recommendations of the ERS/ATS taskforce on outcomes for COPD 
pharmacological trials [30], following inhaled UFH therapy for 21-days compared with placebo.  
 
Secondary objectives were to demonstrate improvements in exercise capacity evaluated as the distance 
covered in 6 min (6MWD) and dyspnoea (Borg score), with no significant change in blood coagulation 
parameters, compared with placebo. Further secondary objectives were the influence of UFH on post-
exercise pulse oximeter saturation (SpO2) and heart rate.    
 
At day 1 spirometry was performed before the treatment, and 1 hour and 4 hours post treatment, and 
blood samples were taken. On day 1 and 21, the 6MWD and Borg questionnaire were assessed.  Patients 
continued with inhaled therapy every 12 hours for 21 days, with weekly coagulation and spirometry testing.  
The same spirometry and coagulation tests were performed at the follow-up visit one week after the end of 
the treatment period. 
 
Statistical analysis 
Values were reported as means and standard error of the mean (SEM). Two-way analysis of variance 
(ANOVA) with Bonferroni post-test and t-test were used for treatment and point-by-point comparisons, 
respectively, for the treated patients. The statistical significance was defined as P<0.05, and all data 
analyses were performed by using the computer software GraphPad Prism version 5.00 for Mac (CA, USA). 
 
Results 
In our pre-clinical study, protamine sulphate in 1:1 and 2:1 w:w ratios, those used clinically to neutralise 
heparin overdose, neutralised the inhibitory effect of heparin (0.5 µg/ml) on Factor Xa activity (Figure 1A), 
validating the assay we used.  We initially confirmed the effect of PF-4 on heparin activity. It has been 
known for a long time that PF-4 neutralises the anticoagulant activity of heparin and it was first 
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demonstrated that 10 μg of purified PF-4 neutralised 1 μg of heparin [27]. In our assay we show that PF-4 
completely neutralised the anticoagulant activity of heparin in the same ratio (Figure 1B). 
 
Further, we tested the effect of basic peptides and proteins, lactoferrin, IL-8 and polyarginine as a model 
for arginine rich ECP, found in abundance in the inflamed COPD airway. Lactoferrin at 10 μg/ml completely 
neutralised the anticoagulant activity of heparin (Figure 1C).  On a molar basis lactoferrin is as potent as 
protamine sulphate in this effect.  Polyarginine (molecular weight 15,000 – 70,000), when added at 5 μg/ml 
completely neutralised the anticoagulant activity of heparin (Figure 1D). IL-8, another basic chemokine, was 
not as effective as PF-4 in neutralising heparin anticoagulant activity and only at concentrations higher than 
50 μg/ml was IL-8 able to neutralise the activity of heparin. Complete inhibition was seen at 90 μg/ml 
(Figure 1E). 
 
In our clinical study, a total of 40 patients were randomised to receive treatments. Overall, 60.0% of 
patients completed the study (75% placebo; 46.2% heparin 75,000 IU and 60% heparin 150,000 IU). The 
majority of treatment discontinuations (56.3%) were related to a high degree of poor compliance with the 
time for nebulisation (~30 minutes) amongst recruited patients, but were not related to drug treatment 
(Figure 2). Table 1 shows the baseline characteristics of COPD patients enrolled in the study from February 
2012 to March 2015. In the group of patients treated with heparin at the higher dose, by chance, the FEV1 
value expressed as % predicted was significantly lower (P<0.05) compared to the placebo group at the start 
of the study, although this difference was not statistically significant when FEV1 was expressed as L (P>0.05 
vs. placebo).  
 
Impact of inhaled heparin on FEV1 and FVC 
Inhaled heparin (150,000 IU) significantly enhanced change from baseline of trough FEV1 after 7 days of 
treatment compared with placebo treated patients (+249±69 ml, P<0.05) and baseline (+144±69 ml, 
P<0.05) (Figure 3A). Heparin administered at the higher dose also significantly (P<0.05) increased the 
change from baseline of trough FEV1 during the study period, compared with placebo treated patients, and 
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this effect was sustained and even greater at the follow-up visit (+99±131 ml vs. day 21, P>0.05) (Figure 3A 
and B).  
 
Inhaled heparin administered at both low and high doses significantly enhanced the change from baseline 
of trough FVC after 7 days of treatment compared with placebo treated patients (overall +441±163 ml, 
P<0.05) and baseline (overall +236±163 ml) (Figure 3C). Heparin (75,000 IU and 150,000 IU) also 
significantly (P<0.01) increased the change from baseline of trough FVC during the study period, compared 
with placebo. The effect of heparin administered at the higher dose was sustained and also greater at the 
follow-up visit (+105±213 ml vs. day 21, P>0.05) (Figure 3C and D). Conversely, heparin at the lower dose 
appeared to have a phasic effect on FEV1 and FVC which were reduced at day 14 and day 28, compared to 
day 7 and 21 respectively. 
 
As previously reported [31], water inhalation (7 ml), did not induce either an acute bronchoconstrictor or a 
broncholytic effect over the first 4h post administration during the study period.  Heparin inhalation also 
did not induce any acute effect on lung function. 
 
Impact of inhaled heparin on exercise capacity  
Inhaled heparin significantly (P<0.05) increased the 6MWD, compared with the 6MWD covered at baseline 
(placebo -2±31, heparin 75,000 IU +85±38 m, and heparin 150,000 IU +123±26 m), and significantly 
(P<0.001) improved the post-exercise dyspnoea measured by the Borg score, compared with baseline 
(placebo -2.0±0.8, heparin 75,000 IU -3.8±0.4, and heparin 150,000 IU -3.1±0.5) (Figure 4A and B). 
 
At day 21, inhaled heparin also improved the post-exercise SpO2, compared with T0. The tendency of SpO2 
values from T0 to T21 was positive in patients receiving heparin. Indeed, the patient-by-patient analysis 
showed that in patients receiving heparin at the higher dose, this positive trend was significantly (P<0.05) 
different compared with the negative tendency of the placebo group (Figure 4C and D). 
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Impact of inhaled heparin on haematology and blood coagulation parameters 
Overall, inhaled heparin did not negatively influence either haematology or blood coagulation parameters. 
At day 21, only the concentration of hemoglobin was significantly (P<0.05) higher in the arm of patients 
treated with heparin 75,000 IU compared with that of the placebo treated group (see Table E1 in the on-
line supplement).  
 
Adverse events 
The administration of inhaled heparin at both low and high doses did not induce any serious adverse 
events. No significant (P>0.05) differences were detected with regard to adverse events such as 
cardiovascular, coagulation or respiratory disorders, between the patients treated with heparin at either 
dose and the placebo group (Table 2). 
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Figure 1. The anticoagulant activity of heparin measured as inhibition of Factor Xa activity is neutralised by 
(A) protamine sulphate (PS), (B) platelet factor-4 (PF4), (C) lactoferrin (LF), (D) polyarginine (PArg) and (E) IL-
8 in the concentration ranges shown. **; p<0.01 vs PBS control, n=3 for all except n=4 for PS. 
 
 
 
 
 
 
 
Figure 2. Study profile. 
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Figure 3. Influence of inhaled heparin on change from baseline of trough FEV1 (upper panels) and FVC 
(lower panels) during the study period (A and C) and at follow-up (B and D). Data expressed as mean±SEM. 
* P<0.05 and ** P<0.01 vs. placebo. Statistical significance assessed by two-way ANOVA with Bonferroni 
post-test. 
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Figure 4. Influence of inhaled heparin on 6MWD (A), post-exercise Borg score (B), post-exercise SpO2 (C), 
and post-exercise heart rate (D). Data expressed as mean±SEM. * P<0.05, ** P<0.01 and *** P<0.001 vs. 
T0. Statistical significance assessed by t test. 
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Discussion 
No clinical study to date has indicated adverse events or harm associated with the use of inhaled heparin 
[25, 26].  Our pre-clinical studies indicate this may be due to the presence of basic proteins with the 
capacity to neutralise the anticoagulant activity of UFH and the subsequent risk of hemoptysis in normal 
and inflamed airways.  
Platelets are a rich source of PF-4, and platelets are known to be activated in COPD [32]. It has been known 
for a long time that PF-4 neutralises the anticoagulant activity of heparin in a 10:1 w:w ratio [27] and we 
confirmed this observation using the assay described above. Levels of ECP are high in COPD sputum, and 
ECP concentrations of 85.4 (49.6-319.5 μg/ml) are reported in stable COPD which increase significantly to 
187.0 (81.3-295) on exacerbation [33]. Polyarginine, a model of arginine rich ECP, also neutralised the anti-
coagulant activity of heparin in the same 10:1 w:w ratio as PF-4. 
Lactoferrin is found in respiratory secretion at high concentrations (0.1 to 1.0 mg/ml) [34] and in COPD 
sputum at up to 300 μg/ml [35].  Lactoferrin at 10 μg/ml (20:1 w:w ratio with heparin) completely 
neutralised the anticoagulant activity of heparin, and on a molar basis, lactoferrin was nearly as potent as 
protamine sulphate. IL-8 is a chemokine present in high concentrations in COPD sputum [33].  IL-8 was 
present at 1.5 (0.9-4.4 μg/ml) in stable disease and this increased significantly to 7.78 (3.52-9.90) μg/ml on 
bacterial exacerbation. However, IL-8 was not as effective as PF4 in neutralising heparin anticoagulant 
activity and only at concentrations higher than 50 μg/ml was IL-8 able to neutralise the activity of heparin. 
However, the inflamed COPD airways contain multiple basic chemokines which overall may contribute to 
neutralising the anticoagulant activity of inhaled heparin [36]. 
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The anticoagulant activity of heparin is associated with only one in three heparin chains and appears to 
play a minor role in many clinical uses and in physiological and pathological responses [37].  Our in vitro 
evidence is that the anti-coagulation activity of heparin is inhibited by basic proteins in sputum, leaving its 
other pharmacological anti-inflammatory and mucolytic activities, intact.  Anti-coagulation effects are 
normally achieved at lower doses than either anti-inflammatory effects or mucolytic effects.  Heparin 
dissolves F-actin and DNA bundles, activates DNase and reduces the viscosity of cystic fibrosis sputum [15]. 
We have observed the same effect of heparin on DNA in sputum from patients with COPD (unpublished 
observations). These effects are achieved at heparin concentrations of 1 mg/ml in sputum [15] and are not 
inhibited by basic proteins present at the concentrations indicated above, and are therefore independent 
of anticoagulant activity.  
In our clinical study, inhaled nebulised UFH administered at 150,000 IU twice a day for 21 days significantly 
improved FEV1, and both 75,000 IU and 150,000 IU twice a day for 21 days significantly improved FVC.  The 
apparent biphasic effect of the lower dose may reflect the balance between achieving mucus clearance at 
this dose, and the uptake and sequestration of heparin [38] and large heparin/basic protein complexes [39] 
by pulmonary macrophages. At the higher dose the availability of heparin may not be limited to the same 
extent by this cellular storage mechanism and the effect is sustained.  
Patients with moderate to severe COPD produce 20-100 ml sputum a day, (mean 39 ml [41]) which requires 
delivery of 20-100 mg heparin to the airway to deliver an effective (1 mg/ml) dose. In our study, heparin 
was delivered from a jet nebuliser, reported to deliver 8% [40] of the loading dose (150,000 IU, 750 mg) to 
the lungs i.e. 12,000 IU, 60 mg, to achieve a therapeutic concentration ~1.5 mg/ml in the airway.  Effects of 
inhaled heparin on systemic coagulation were previously reported only for much higher doses (>8 mg/kg 
body weight) [38].  In parallel, our study found no effect of inhaled heparin at either dose on systemic 
coagulation parameters. 
Pulmonary rehabilitation (PR) alone for 3 weeks had no effect on FEV1 as we [29], and others [42], 
previously reported for PR programmes. Although improvements in post-exercise Borg score indicated 
improvement in dyspnoea, the 6MWD was not improved.  Guidelines recommend 6-12 weeks of PR 
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therapy [43] and improvements in 6MWD are seen after these longer PR programmes [42].   However, 
more recently, intensive 7-days a week 3-week PR programmes were reported [44, 45] to significantly 
improve both FEV1 and 6MWD in COPD patients with a wide range of disease severity.  The addition of UFH 
at the highest dose for 7 days to PR resulted in a clinically significant improvement in FEV1 of 144 ml from 
baseline, which was maintained over the course of the study and at follow-up.   
 
All the patients in our trial were receiving concomitant medication with salbutamol (1 mg twice daily via 
nebulisation) and beclomethasone dipropionate (400 µg twice daily via nebulisation), as well as pulmonary 
rehabilitation.  Mucus clearance devices were previously shown to increase response to bronchodilator 
therapy in COPD patients [46]. We speculate, therefore, that the beneficial effect of inhaled UFH observed 
in this study may be the result of the mucolytic activity of heparin [15], since mucolytic activity aids mucus 
clearance from the airways, reducing airway obstruction, and enhances bronchodilator/ICS delivery to 
target cells, with effects on lung function.  
World-wide, the prevalence of patients with COPD GOLD stage II or higher is estimated at 10%, and a 
growing cause of morbidity and mortality [1].  It is clear that new therapeutic approaches are needed to 
alter the course of the disease, and the progressive loss of lung function leading to invalidity and death.  
Cough and sputum production are risk factors for poor outcomes in COPD [47] and it has been suggested 
that mucus hypersecretion should be a therapeutic target in all patients with COPD [48].  Recent meta-
analyses indicate that mucolytics may reduce the number of exacerbations in patients with chronic 
bronchitis or COPD, and may have an effect on the duration and severity of exacerbations [3, 49, 50].  This 
is reflected in the most recent (2015) GOLD guidelines [3] indicating that exacerbations may be reduced by 
treatment with mucolytics such as N-acetyl cysteine, erdosteine and carbocysteine.  It is not known, 
however, whether the clinical effect of these oral mucolytics also relates to their anti-oxidant properties 
[51].  
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Heparin administered at both doses significantly increased the 6MWD and reduced the post-exercise Borg 
score. The recommended minimal clinically important difference (MCID) is conservatively estimated to be 
54–80 meters for the distance covered during the 6MWD assessment and 1-unit for the Borg score [52,53]. 
The change induced by both the doses of heparin in 6MWD indicated a clinically significant change in 
functional status [54] in the arms that received the active treatments, compared with the placebo group. 
Analogously, the improvement induced by heparin in the post-exercise Borg score suggested a clinically 
significant improvement in dyspnoea [55].  In fact, both doses of heparin reduced the Borg score of a 
further 1-unit as compared with the effect of the respiratory rehabilitation program detectable in the 
placebo group. Furthermore, heparin administered at the higher dose also significantly improved the post-
exercise SpO2 tendency, compared with placebo.  
Bronchodilators improve the 6MWD [53] and the observed improvement is therefore likely to be related to 
inhaled heparin,  alone or in combination with concomitant use of a bronchodilator. 
UFH is a drug with a structurally diverse molecular scaffold naturally oriented to multiple targets, with 
mucolytic [15], wound healing, anti-inflammatory [14] and anti-oxidant [56] pharmacological activities 
when inhaled directly into the airways.  The observed clinically significant improvements over a relatively 
short time in lung function, with improvements in patient-centred outcomes, in COPD may reflect this 
unique pharmacological profile.  Although this RCT cannot define the mechanism of action of inhaled 
heparin, we hypothesise that the observed effects of inhaled heparin were at least partly due to the 
mucolytic properties of heparin, as well as the anti-inflammatory effects of heparin [14], including 
inhibition of neutrophil elastase [57], a potent mucus secretagogue and elastolytic inducer of emphysema 
[36, 58].  Further, it has been hypothesised that afferent C-fibres are stimulated by inflamed airways in 
COPD, and play a role in excessive mucus secretion, airways obstruction, rapid shallow breathing, skeletal 
myopathy and CO2 retention, especially during acute exacerbations [59]. In this case we can speculate that 
inhaled heparin neutralised the cationic proteins, including ECP, capable of C-fibre stimulation [60].    
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Although pre-clinical studies have indicated the long-term safety of inhaled heparin [38] further clinical 
studies are needed to confirm the long term safety of inhaled heparin in patients with COPD. 
 
Concluding, the results of this RCT indicate that inhaled nebulised UFH improves the pulmonary function, 
exercise capacity and dyspnoea in patients with moderate to very severe COPD, with no significant changes 
in blood coagulation parameters, and a good safety profile.  
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Tables 
Table 1. Patient demographic and baseline characteristics. 
 Placebo (n=12) 
Heparin 75000 IU 
(n=13) 
Heparin 150000 IU 
(n=15) 
Overall (n=40) 
Age (years) 71.55±1.59 72.54±2.46 72.00±2.30 72.05±1.25 
Male/female 9/3 9/4 9/6 27/13 
Current smokers (n) 3 4 3 10 
Pack-years 56.39±10.34 56.93±9.35 45.87±7.53 56.65±5.12 
C-reactive protein 
(mg/L) 
3.01±1.81 2.26±.98 1.20±0.55 2.10±0.67 
FEV1 (%predicted) 50.45±3.12 48.57±2.25 41.53±2.51 * 46.50±1.60 
FEV1 (L) 1.24±0.13 1.21±0.09 0.97±0.07 1.13±0.06 
FEV1/FVC (%) 52.9±3.6 50.9±2.4 48.6±2.7 50.6±1.7 
     
Data expressed as mean±SEM. * P<0.05 vs. placebo. 
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Table 2. Summary of adverse events. 
 Placebo Heparin 75,000 IU Heparin 150,000 IU 
Serious adverse events 0 0 0 
    
Further adverse events:    
Cardiovascular disorders    
Hypotension 0 1 0 
Coagulation disorders    
Epistaxis 1 1 1 
Hemoptysis 0 0 1 
Respiratory disorders    
COPD exacerbation 1 0 0 
Pneumonia 0 0 1 
Others    
Tibial fracture 0 1 0 
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